For more on treatment delivery, see our guide to GLP-1 injections explained
Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months
This uniformity is crucial for several reasons: - Reliability: Patients and healthcare providers can trust that each dose of semaglutide will have the same therapeutic effect, which is essential for managing chronic conditions like diabetes and obesity
The Future of Personalized Metabolic Medicine Were standing at a pivotal moment in metabolic medicine where personalization, prevention, and patient-centered care are becoming the new standard
Some people experience barely noticeable queasiness, while others describe a stronger sensation that temporarily affects appetite
Accidental temperature excursions instances where a refrigerated medicine has been left at room temperature are a common concern for patients using injectable therapies